Link Between Omega-3 Fatty Acids and Increased Prostate Cancer Risk Confirmed

Consumption of fatty fish and fish-oil supplements linked to 71 percent higher risk: 

Alan Kristal

Senior author Alan Kristal, Dr.P.H., is a member of the Public Health Sciences Division at Fred Hutch.

A second large, prospective study by scientists at Fred Hutchinson Cancer Research Center has confirmed the link between high blood concentrations of omega-3 fatty acids and an increased risk of prostate cancer.

Published in the online edition of the Journal of the National Cancer Institute, the latest findings indicate that high concentrations of EPA, DPA and DHA – the three anti-inflammatory and metabolically related fatty acids derived from fatty fish and fish-oil supplements – are associated with a 71 percent increased risk of high-grade prostate cancer. The study also found a 44 percent increase in the risk of low-grade prostate cancer and an overall 43 percent increase in risk for all prostate cancers.

The increase in risk for high-grade prostate cancer is important because those tumors are more likely to be fatal.

The findings confirm a 2011 study published by the same Fred Hutch scientific team that reported a similar link between high blood concentrations of DHA and a more than doubling of the risk for developing high-grade prostate cancer. The latest study also confirms results from a large European study.

“The consistency of these findings suggests that these fatty acids are involved in prostate tumorigenesis and recommendations to increase long-chain omega-3 fatty acid intake, in particular through supplementation, should consider its potential risks,” the authors wrote.

“We’ve shown once again that use of nutritional supplements may be harmful,” said Alan Kristal, Dr.P.H., the paper’s senior author and member of the Fred Hutch Public Health Sciences Division. Kristal also noted a recent analysis published in the Journal of the American Medical Association that questioned the benefit of omega-3 supplementation for cardiovascular diseases. The analysis, which combined the data from 20 studies, found no reduction in all-cause mortality, heart attacks or strokes.

Theodore Brasky

Corresponding author Theodore Brasky, Ph.D., a research assistant professor at The Ohio State University Comprehensive Cancer Center, was a postdoctoral trainee at Fred Hutch when the research was conducted.

“What’s important is that we have been able to replicate our findings from 2011 and we have confirmed that marine omega-3 fatty acids play a role in prostate cancer occurrence,” said corresponding author Theodore Brasky, Ph.D., a research assistant professor at The Ohio State University Comprehensive Cancer Center who was a postdoctoral trainee at Fred Hutch when the research was conducted. “It’s important to note, however, that these results do not address the question of whether omega-3’s play a detrimental role in prostate cancer prognosis,” he said.

Kristal said the findings in both Fred Hutch studies were surprising because omega-3 fatty acids are believed to have a host of positive health effects based on their anti-inflammatory properties. Inflammation plays a role in the development and growth of many cancers.

It is unclear from this study why high levels of omega-3 fatty acids would increase prostate cancer risk, according to the authors, however the replication of this finding in two large studies indicates the need for further research into possible mechanisms. One potentially harmful effect of omega-3 fatty acids is their conversion into compounds that can cause damage to cells and DNA, and their role in immunosuppression. Whether these effects impact cancer risk is not known.

The difference in blood concentrations of omega-3 fatty acids between the lowest and highest risk groups was about 2.5 percentage points  (3.2 percent vs. 5.7 percent), which is somewhat larger than the effect of eating salmon twice a week, Kristal said.

The current study analyzed data and specimens collected from men who participated in the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a large randomized, placebo-controlled trial to test whether selenium and vitamin E, either alone or combined, reduced prostate cancer risk. That study showed no benefit from selenium intake and an increase in prostate cancers in men who took vitamin E.

The group included in this analysis consisted of 834 men who had been diagnosed with incident, primary prostate cancers (156 were high-grade cancer) along with a comparison group of 1,393 men selected randomly from the 35,500 participants in SELECT.

The National Cancer Institute and the National Center for Complementary and Alternative Medicine funded the research.

Also participating in the study were additional Fred Hutch scientists and researchers from the University of Texas, University of California, University of Washington, National Cancer Institute and the Cleveland Clinic.

 Fish oil linked to prostate cancer. NBC’s Dr. Nancy Snyderman reports.

 

References

Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR. Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial. J Natl Cancer Inst 2013 Jul 10. [Epub ahead of print]

Brasky TM, Till C, White E, Neuhouser ML, Song X, Goodman P, Thompson IM, King IB, Albanes D, Kristal AR. Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol 2011; 173: 1429-39.

Council for Responsible Nutrition. CRN Says New Study on Omega-3 Conclusions Are Overblown. Press Release, July 11, 2013.

 

Why fish is so good for you

Scientists of Friedrich Schiller University Jena and Jena University Hospital decode the antihypertensive impact of omega-3 fatty acids.

Scientists of Jena University and Jena University Hospital now analyzed the impact of omega-3 fatty acids and described the underlying molecular mechanisms for the first time.

Scientists of Jena University and Jena University Hospital now analyzed the impact of omega-3 fatty acids and described the underlying molecular mechanisms for the first time.

Fish is healthy: easy to digest and with a high level of precious proteins, fish is considered an important part of a healthy diet. And with the so-called omega-3 fatty acids fish contains real ‘fountains of youth’. These fatty acids – like docosahexaeonic acid (DHA) occur mostly in fatty fish like herring, salmon and mackerel. They are thought to lower the blood pressure, to strengthen the immune system and to have positive effects on the development on the nervous system and the cardiovascular system.

“Clinical studies about the intake of nutritional supplements containing omega-3 fatty acids haven’t provided complete clarity so far,” Prof. Dr. Stefan H. Heinemann from Friedrich Schiller University Jena (Germany) says. “The molecular impact of the omega-3 fatty acids isn’t fully understood yet,” the biophysicist continues. But now scientists of the DFG research group FOR 1738 based at Jena University are able to bring new facts to light: in two newly published articles for the well-known science magazine ‘Proceedings of the National Academy of Sciences, USA’ they describe how they analyzed the impact of omega-3 fatty acids on a systemic level and they also described the underlying molecular mechanisms for the first time.

The teams around Prof. Heinemann (Jena University), Prof. Dr. Michael Bauer (Jena University Hospital) and Prof. Dr. Toshinori Hoshi (University of Pennsylvania) were able to show that the so-called ‘SLO1′ potassium channel is an important component in the effectiveness of omega-3 fatty acids. “These ionic channels act like very specific receptors for DHA and are opened by the binding of the omega-3 fatty acids,” Biophysicist Heinemann explains. In the case of other omega-3 fatty acids – like the shorter eicosapentaenoic acid (EPA) or the alpha-linolenic acid (ALA) extracted from plants – the impact is much weaker.

Prof. Bauer and his colleagues examined the effects of omega-3 fatty acids on SLO1 channels of the cardiovascular system by experimenting with mice. “Administration of DHA should result in an expansion of the blood vessels and consequently a drop in blood pressure,” the physician says. The laboratory experiments confirmed exactly that. In genetically modified mice however, which were not able to produce the SLO1 channel, the antihypertensive impact of DHA failed to appear. “Thus we were able to show for the first time that DHA directly influences the blood pressure, which is being mediated through SLO1 channels,” Bauer summarizes.

Beyond that, the scientists made another surprising discovery: a variant of DHA, which can often be found in nutritional supplements containing omega-3 fatty acids, doesn’t show an antihypertensive effect. Moreover, it suppresses and even diminishes the effect of the natural DHA from fish oil. “The intake of non-natural omega-3 fatty acids can therefore also have counter-productive effects,” Prof. Bauer stresses. This is of particular importance for the nutritional supplements of patients in intensive care who are being drip-fed: their supplements of omega-3 fatty acids should be specifically aimed at and adapted to the patients’ clinical requirements.

 

References

Hoshi T, Wissuwa B, Tian T, Tajima N, Xu R, Bauer M, Heinemann SH, Hou S (2013) Omega-3 fatty acids lower blood pressure by directly activating large-conductance Ca2+-dependent K+ channelsProceedings of the National Academy of Sciences USA (DOI: 10.1073/pnas.1221997110)

Hoshi T, Tian T, Xu R, Heinemann SH, Hou S (2013) Mechanism of the modulation of BK potassium channel complexes with different auxiliary subunit compositions by the omega-3 fatty acid DHAProceedings of the National Academy of Sciences USA (DOI: 10.1073/pnas.1222003110)

 

Omega-3 Intake Heightens Working Memory in Healthy Young Adults

University of Pittsburgh researchers publish first-ever Omega-3 study on a population at the “top of its cognitive game”. 

While Omega-3 essential fatty acids—found in foods like wild fish and grass-fed livestock—are necessary for human body functioning, their effects on the working memory of healthy young adults have not been studied until now.

In the first study of its kind, researchers at the University of Pittsburgh have determined that healthy young adults ages 18-25 can improve their working memory even further by increasing their Omega-3 fatty acid intake. Their findings have been published online in PLOS One.

“Before seeing this data, I would have said it was impossible to move young healthy individuals above their cognitive best,” said Bita Moghaddam, project investigator and professor of neuroscience. “We found that members of this population can enhance their working memory performance even further, despite their already being at the top of their cognitive game.”

Led by Rajesh Narendarn, project principal investigator and associate professor of radiology, the Pitt research team sought healthy young men and women from all ethnicities to boost their Omega-3 intake with supplements for six months. They were monitored monthly through phone calls and outpatient procedures.

Before they began taking the supplements, all participants underwent positron emission tomography (PET) imaging, and their blood samples were analyzed. They were then asked to perform a working memory test in which they were shown a series of letters and numbers. The young adults had to keep track of what appeared one, two, and three times prior, known as a simple “n-back test.”

“What was particularly interesting about the presupplementation n-back test was that it correlated positively with plasma Omega-3,” said Moghaddam. “This means that the Omega-3s they were getting from their diet already positively correlated with their working memory.”

After six months of taking Lovaza—an Omega-3 supplement approved by the Federal Drug Administration—the participants were asked to complete this series of outpatient procedures again. It was during this last stage, during the working memory test and blood sampling, that the improved working memory of this population was revealed.

“So many of the previous studies have been done with the elderly or people with medical conditions, leaving this unique population of young adults unaddressed,” said Matthew Muldoon, project coinvestigator and associate professor of medicine at Pitt. “But what about our highest-functioning periods? Can we help the brain achieve its full potential by adapting our healthy behaviors in our young adult life? We found that we absolutely can.”

Although the effects of Omega-3s on young people were a focus, the Pitt team was also hoping to determine the brain mechanism associated with Omega-3 regulation. Previous rodent studies suggested that removing Omega-3 from the diet might reduce dopamine storage (the neurotransmitter associated with mood as well as working memory) and decrease density in the striatal vesicular monoamine transporter type 2 (commonly referred to as VMAT2, a protein associated with decision making). Therefore, the Pitt researchers posited that increasing VMAT2 protein was the mechanism of action that boosted cognitive performance. Unfortunately, PET imaging revealed this was not the case.

“It is really interesting that diets enriched with Omega-3 fatty acid can enhance cognition in highly functional young individuals,” said Narendarn. “Nevertheless, it was a bit disappointing that our imaging studies were unable to clarify the mechanisms by which it enhances working memory.”

Ongoing animal modeling studies in the Moghaddam lab indicate that brain mechanisms that are affected by Omega-3s may be differently influenced in adolescents and young adults than they are in older adults. With this in mind, the Pitt team will continue to evaluate the effect of Omega-3 fatty acids in this younger population to find the mechanism that improves cognition.

Other Pitt researchers involved in the project include William G. Frankle, professor of psychiatry, and Neal S. Mason, research assistant professor of radiology.

 

Reference

Narendran R, Frankle WG, Mason NS, Muldoon MF, Moghaddam B. Improved working memory but no effect on striatal vesicular monoamine transporter type 2 after omega-3 polyunsaturated Fatty Acid supplementation. PLoS One. 2012;7(10):e46832. doi: 10.1371/journal.pone.0046832. Epub 2012 Oct 3.

Good Diets Fight Bad Alzheimer Genes

Diets high in fish oil have a beneficial effect in patients at risk

Scientists today agree that there are five molecules that are known to affect or cause Alzheimer’s disease, which plagues an estimated five million Americans. The potency of these molecules is linked to environmental factors such as diet and lifestyle.

Professor Daniel Michaelson of Tel Aviv University’s Department of Neurobiologyat the George S. Wise Faculty of Life Sciences has illuminating news about one of these five molecules — APOE, created by the apolipoprotein E gene found in all of our bodies.

Professor Michaelson says APOE comes in two forms, a “good” APOE gene and a “bad” APOE gene, called APOE4. He has developed animal models to investigate the effects of diet and environment on carriers of APOE4, the presence of which is a known risk factor for Alzheimer’s. It appears in 50% of all Alzheimer’s patients, and in 15% of the general population which due to APOE4 is the population which is at risk of getting the disease.

The good news? A diet high in Omega 3 oils and low in cholesterol appears to significantly reduce the negative effects of the APOE4 gene in mouse models.

Exercise is not enough — and may be worse

Prof. Daniel Michaelson

In differentiating between the good and bad variants of the APOE gene, Professor Michaelson and his team studied many variables. They determined that while a rich and stimulating environment is good for carriers of “good” APOE, the same environment has a negative effect on those at risk for Alzheimer’s because they carry the APOE4 gene. While this environment stimulated the formation of new neuronal connections in the “good APOE” mice, it caused the death of brain neurons in the “bad APOE” mice. The stimulating environment included running wheels and tubes for hiding and sliding, as well as ropes and other toys for the mice to play on, replaced and updated with new toys weekly. Those in a non-stimulating environment had access to no toys at all.

“Conditions that are generally considered good can be harmful if the mouse is a carrier of the APOE4 gene. Extrapolating this to the human population, individuals with the bad APOE4 gene are more susceptible to stress caused by an environment that stimulates their brain,” says Professor Michaelson.

The following is an abstract of a study by the research group of Professor Michaelson. The study is published in Journal of Alzheimer’s Disease (2012; 28 (3): 667-83):

“Apolipoprotein E4 (apoE4) is the most prevalent genetic risk factor for Alzheimer’s disease (AD). Epidemiological studies revealed that consumption of docosahexaenoic acid (DHA: 22 : 6 (ω3)), a major brain polyunsaturated fatty acid, is protective for AD and that elevated cholesterol levels are an AD risk factor. We presently investigated the extent to which the pathological effects of apoE4 in vivo can be prevented by consuming fish oil (DHA) or can be modified by cholesterol. Accordingly, apoE3- and apoE4-targeted replacement mice were subjected, following weaning, to a fish oil dietenriched in DHA and to a cholesterol-containing diet under regular and enriched environments. Cholesterol metabolism in the hippocampus and the corresponding phospholipid and fatty acid levels were affected by fish oil (DHA) and cholesterol diets and by environmental stimulation. Importantly, cholesterol metabolism and the fatty acid levels were not affected by apoE4. The phospholipid levels were, however, affected by apoE4. This effect was most pronounced in the cholesterol-fed mice and was abolished by the fish oil (DHA) diet. ApoE4 elevated hippocampal intraneuronal amyloid-β levels under regular conditions and lowered them following environmental stimulation, relative to those of the apoE3 mice. ApoE4 also elevated the levels of the presynaptic transporters Vglut and Vgat, and decreased behavioral performance in an object recognition test. Importantly, all of these apoE4 phenotypes were abolished by the fish oil (DHA) diet, whereas the cholesterol diet modified them. These findings suggest that a fish oil (DHA)diet could be used to attenuate the effects of apoE4 in AD.”

When it’s good, it’s good

“The main take-away message here is that good diets can alleviate the effects of bad genes. Of course nutritionists have had this general idea for a while, but it’s nice to be able to show that this approach can be applied to specifically counteract the negative effects of Alzheimer’s disease-related genes,” says Professor Michaelson.

 

 Reference

Kariv-Inbal Z, Yacobson S, Berkecz R, Peter M, Janaky T, Lütjohann D, Broersen LM, Hartmann T, Michaelson DM. The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol. J Alzheimers Dis 2012; 28 (3): 667-83.

 

Omega-3 Fatty Acids May Help to Reduce the Physical Harm Caused by Smoking

New study presented at the World Congress of Cardiology organized by the World Heart Federation 

Omega-3 fatty acids may help to reduce the physical harm caused by smoking, according to a new study presented yesterday (20 April 2012) at the World Congress of Cardiology in Dubai, United Arab Emirates.

The study, carried out in Greece, assessed the effect of four-week oral treatment with 2 g/day of omega-3 fatty acids on the arterial wall properties of cigarette smokers. The results showed that short-term treatment with omega-3 fatty acids improves arterial stiffness and moderates the acute smoking-induced impairment of vascular elastic properties in smokers.

“These findings suggest that omega-3 fatty acids inhibit the detrimental effects of smoking on arterial function, which is an independent prognostic marker of cardiovascular risk,” said Dr. Gerasimos Siasos, University of Athens Medical School, 1st Department of Cardiology, “Hippokration” Hospital. “The cardioprotective effects of omega-3 fatty acids appear to be due to a synergism between multiple, intricate mechanisms involving anti-inflammatory and anti-atherosclerotic effects. Furthermore, AHA recommends that people without documented history of coronary heart disease should consume a variety of fish (preferably oily – rich in omega-3 fatty acids) at least twice per week.”

The World Heart Federation strongly encourages all smokers to quit,” said Dr Kathryn Taubert, Chief Science Officer at the World Heart Federation. “The only way to protect your body from the harmful effects of tobacco is to stop smoking. We encourage all people, both smokers and non-smokers, to eat healthy diets, which includes foods rich in omega-3 fatty acids.”

 

$29 Billion Reasons to Lie about Cholesterol

Millions of people around the world are currently taking medications to lower their cholesterol. In England alone, around 7 million people are taking cholesterol-lowering statins in the hope of reducing their risk of a heart attack. But an increasing number of doctors and researchers are questioning the supposed link between cholesterol and heart disease.

At the same time, many people are concerned about the mass prescription of medications. In particular, prescribing medications to people who are, for the most part, perfectly healthy.

A team is now working on a documentary about the cholesterol hypothesis.  The documentary will address several key issues: Have the facts about cholesterol and heart disease been distorted by pharmaceutical companies keen to increase their profits? Have our health authorities done their job to protect us from these commercial interests?

29 billion dollars is a conservative estimate of the current value of the cholesterol-lowering industry.

29 billion pounds is what cardiovascular disease costs the UK economy each year.

If the focus on cholesterol has been a mistake, then the greatest cost is associated with the lost opportunity to tackle heart disease.

 

Read More 

$29 Billion Reasons to Lie About Cholesterol29 Billion Reasons to Lie about Cholesterol provides the facts; enabling readers to make informed choices about the prevention of heart disease and diabetes.

Embedly Powered

via Google

 

Low Cholesterol and Infections

by Uffe Ravnskov, M.D., Ph.D.

Several researchers have claimed that statin treatment prevents infections. Recently a Dutch group published an analysis of the statin trials where the authors had reported the number of infections. Not unexpectedly they didn´t find any difference between the statin groups and the controls (those who got an ineffective placebo pill).

In an editorial in the same issue of British Medical Journal, where the Dutch report was published, Beatrice Golomb commented the study. It was certainly not expected either because, as she wrote, a number of relevant factors may distort the results. One of them is the fact that among 632 statin trials, only eleven reported the number of infections, and “most authors declined to provide the omitted information when approached”. “The best evidence”, she concluded, “is that statins should not be used to forestall infection or its consequences.” 

There is even evidence of the opposite. As Golomb also pointed out, low cholesterol is a risk factor for infection, and as we have a plausible mechanism to propose, we send a letter to British Medical Journal, now published as a Rapid Response.

If you sympathize with our letter you are most welcome to vote (on the right hand column). Many positive votes may possibly increase its chance to become published in the paper version as well.

 

Uffe Ravnskov, MD, PhD, independent investigator
President of THINCS, The International Network of Cholesterol Skeptics
Magle Stora Kyrkogata 9, 22350 Lund, Sweden
tel +46 46145022  or  +46-702580416
www.ravnskov.nu/uffe


Low Cholesterol and Cancer

by Uffe Ravnskov, M.D., Ph.D.

In many western countries more and more get cancer although at the same time more and more people stop smoking, one of  the most cancer provoking factors. Members of The International Network of Cholesterol Skeptics think that the reason is the increasing use of cholesterol lowering drugs. Those who promote such treatment argue that no analysis of the statin trials have shown any association and some even claim that the statins protect against cancer.

There are many ways to cover up the fact that lowering cholesterol may lead to cancer, but there are also numerous observations that point to low cholesterol as the villain.

But how can low cholesterol lead to cancer? This is a good question, and there is an answer. The reason is that the lipoproteins partake in the immune defense system, and because many cancers are caused by virus or bacteria.

Together with two members of THINCS, Kilmer McCully, the discoverer of the association between homocysteine and atherosclerosis, and Paul Rosch, President of the American Institute of Stress, I have tried to present the facts around this issue. The paper has finally been published in Quarterly Journal of Medicine. Before that, we sent the paper to six different medical journals (not at the same time of course), all of which rejected it. Here are their arguments:

Archives of Internal Medicine: I regret to inform you that its priority rating is not sufficiently high to warrant our considering it further for publication. Based on our initial review, we will not be sending the paper for additional outside editorial review.

CA: A Cancer Journal for Clinicians: Thank you for submitting your proposal for an article on “Low cholesterol, cancer and the role of lipoproteins” to CA: A Cancer Journal for Clinicians. It is our editorial policy to concentrate on articles that address cancer more broadly (treatment modalities used for many cancer types, current treatment of common types of cancer, public health issues relevant to several cancer types, etc.). For these reasons, we cannot consider your article for publication in CA. However, you may want to consider submitting your article to CANCER, another peer-reviewed American Cancer Society journal, which publishes more focused papers such as the one you have described.

Cancer: Thank you for your recent manuscript submission of “Low cholesterol, cancer and the role of lipoproteins” (CNCR-11-2485) to Cancer.  Your paper has undergone initial review. I am sorry to report that it was not deemed to be of broad enough interest to our readership to merit further evaluation.

JAMA: Thank you for your inquiry. However, JAMA is not able to consider your manuscript for publication.

Journal of the National Cancer Institute: I am sorry that we shall not be able to use the above-titled manuscript. After careful evaluation, the Editorial Board did not accord it a priority sufficient for further consideration.

Scandinavian Cardiovascular Journal:  Thank you for submitting the manuscript # SCAR-2011-0151 entitled “Low cholesterol, cancer and the crucial role of lipoproteins” to the Scandinavian Cardiovascular Journal. The questions raised are important, indeed, and deserve a thorough analysis and discussion. Admittedly not being an expert on this field, my impression is that the present manuscript is polemic in style, and biased. This view was shared by one leading cancer epidemiologist; he/she finds the present selection and interpretation of the literature superficial and subjective. Hence I choose not to forward your manuscript to our reviewers.

Read the paper yourself and tell me if it the paper is not “of broad enough interest” or if it is “polemic in style” or if “its priority rating is not sufficiently high”

What I have told you here is no exception. Many of our members including myself can tell you about how difficult it is to publish papers that go counter to conventional wisdom.

 

Uffe Ravnskov, MD, PhD, independent investigator
Spokesman; THINCS, The International Network of Cholesterol Skeptics
Magle Stora Kyrkogata 9, 22350 Lund, Sweden
tel +46 46145022  or  +46-702580416
www.ravnskov.nu/uffe

 

Reference

Ravnskov U, McCully KS, Rosch PJ. The statin-low cholesterol-cancer conundrum. QJM. 2011 Dec 8. [Epub ahead of print]

 

Mother’s Diet Influences Baby’s Allergies — New Research

A possible link between what a mother eats during pregnancy and the risk of her child developing allergies has been identified in new research published in this month’s The Journal of Physiology.

The research found that if a mother’s diet contains a certain group of polyunsaturated fatty acids (PUFAs) – such as those found in fish, walnut oil or flaxseed – the baby’s gut develops differently. The PUFAs are thought to improve how gut immune cells respond to bacteria and foreign substances, making the baby less likely to suffer from allergies.

Until now, several clinical trials have shown that fish and walnut oil supplementation in pregnant women reduces the risk of allergy in their children, but the mechanism was unknown.

“There is intense research interest in maternal diet during pregnancy. In the western diet, the group of polyunsaturated fatty acids that we have shown to help gut function are actually disappearing – our dietary intake of fish and nut oils is being replaced by corn oils which contain a different kind of fatty acid”. Said Dr Gaëlle Boudry, of the INRA research institute in Rennes, France.

“Our study identifies that a certain group of polyunsaturated fatty acids – known as n-3PUFAs – causes a change in how a baby’s gut develops, which in turn might change how the gut immune system develops. These changes are likely to reduce the risk of developing allergies in later life.”

The team found that supplementing a mother’s diet with n-3PUFA caused the new-born’s gut to become more permeable. A more permeable gut enables bacteria and new substances to pass through the lining of the gut into the bloodstream more easily. These new substances then trigger the baby’s immune response and the production of antibodies.

“The end result is that the baby’s immune system may develop and mature faster – leading to better immune function and less likelihood of suffering allergies,” added Dr Boudry.

This research adds to previous studies which have shown that an intake of n-3 PUFAs during pregnancy increases gestational length and maturation of the central nervous system of a baby and that their performance on mental tasks also seemed to be improved in childhood.

“Other studies have found that a diet containing fish or walnut oil during pregnancy may make your baby smarter – our research adds to this, suggesting such supplements also accelerate the development of a healthy immune system to ward off food allergies.”

In terms of next steps, the team’s findings were based on piglets so research will continue to see if they translate to humans. The porcine intestine is an excellent model of the human gut however, so they are hopeful that the findings can be extrapolated. The team also plans to investigate whether the apparent gut function-boosting effects of n-3PUFA that they have identified in new-borns extends into later life.

 

Reference

De Quelen F, Chevalier J, Rolli-Derkinderen M, Mourot J, Neunlist M, Boudry G. n–3 polyunsaturated fatty acids in the maternal diet modify the postnatal development of nervous regulation of intestinal permeability in piglets J Physiol 2011; 589 (17): 4341-4352.

 

Omega-3s Reduce Stroke Severity

A diet rich in omega-3s reduces the severity of brain damage after a stroke, according to a study conducted by Université Laval researchers. The team, co-directed by professors Jasna Kriz and Frédéric Calon, showed that the extent of brain damage following a stroke was reduced by 25% in mice that consumed DHA type omega-3s daily. Details of the study can be found on the website of the journal Stroke.

Researchers observed that the effects of stroke were less severe in mice that had been fed a diet rich in DHA for three months than in mice fed a control diet. In mice from the DHA group, they saw a reduction in the concentrations of molecules that stimulate tissue inflammation and, conversely, a larger quantity of molecules that prevent the activation of cell death.

“This is the first convincing demonstration of the powerful anti-inflammatory effect of DHA in the brain,” underscored Frédéric Calon of Université Laval’s Faculty of Pharmacy. This protective effect results from the substitution of molecules in the neuronal membrane: DHA partially replaces arachidonic acid, an omega-6 fatty acid known for its inflammatory properties.

“The consumption of omega-3s creates an anti-inflammatory and neuroprotective environment in the brain that mitigates damage following a stroke,” summarized Jasna Kriz, of Université Laval’s Faculty of Medicine. “It prevents an acute inflammatory response that, if not controlled, is harmful to brain tissue.”

Professor Calon believes that this anti-inflammatory effect is likely transferable to humans. “Since DHA is readily available, inexpensive, and reduces the risk of a number of health problems without causing significant side effects, the risk–benefit ratio tends to favor the regular consumption of fish or DHA,” he concluded.

 

Reference 

Lalancette-Hébert M, Julien C, Cordeau P, Bohacek I, Weng YC, Calon F, Kriz J. Accumulation of Dietary Docosahexaenoic Acid in the Brain Attenuates Acute Immune Response and Development of Postischemic Neuronal Damage. Stroke 2011 Aug 18. [Epub ahead of print].